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Obesity is characterized by the development of a low-grade chronic inflammatory state in
different metabolic tissues including adipose tissue and liver. This inflammation develops
in response to an excess of nutrient flux and is now recognized as an important link
between obesity and insulin resistance. Several dietary factors like saturated fatty acids
and glucose as well as changes in gut microbiota have been proposed as triggers of this
metabolic inflammation through the activation of pattern-recognition receptors (PRRs),
including Toll-like receptors (TLR), inflammasome, and nucleotide oligomerization domain
(NOD). The consequences are the production of pro-inflammatory cytokines and the
recruitment of immune cells such as macrophages and T lymphocytes in metabolic
tissues. Inflammatory cytokines activate several kinases like IKKβ, mTOR/S6 kinase, and
MAP kinases as well as SOCS proteins that interfere with insulin signaling and action in
adipocytes and hepatocytes. In this review, we summarize recent studies demonstrating
that PRRs and stress kinases are important integrators of metabolic and inflammatory
stress signals in metabolic tissues leading to peripheral and central insulin resistance
and metabolic dysfunction. We discuss recent data obtained with genetically modified
mice and pharmacological approaches suggesting that these inflammatory pathways are
potential novel pharmacological targets for the management of obesity-associated insulin
resistance.
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INTRODUCTION
Obesity is characterized by an excessive adipose tissue expansion
due to an increase in nutrients intake and insufficient energetic
expenditure. Obesity has dramatically increased worldwide and
leads to numerous adverse metabolic disorders including car-
diovascular diseases, type 2 diabetes, and some forms of cancer.
Insulin resistance is associated with obesity and is a central com-
ponent of type 2 diabetes, leading to altered glucose and lipid
metabolism in adipose tissue, liver, and skeletal muscles. Insulin
resistance is characterized by a decrease in insulin signaling
mainly in the Insulin Receptor Substrate (IRS)/PI-3-kinase/PKB
axis that is responsible for most of the metabolic actions of the
hormone (Taniguchi et al., 2006). It is now recognized that a
chronic low-grade systemic and local inflammation that devel-
ops during obesity could connect obesity to the development of
insulin resistance (Gregor and Hotamisligil, 2011). This inflam-
matory state has been reported in different organs involved in
the control of metabolic homeostasis including adipose tissue,
liver, endocrine pancreas, hypothalamus, and possibly skeletal
muscles. The chronic inflammation is caused by an excess of
nutrient intake and has been named metabolic inflammation
or metainflammation (Gregor and Hotamisligil, 2011). Several
dietary factors including saturated fatty acids and glucose as well
as a change in gut microbiota have been proposed as triggers of
this metabolic inflammation that involves both metabolic cells,
such as adipocytes, and a change in the population of immune
cells inmetabolic tissues (Lolmede et al., 2011; Bertola et al., 2012;
Sun et al., 2012). Hypoxia that develops in adipose tissue could
also participate in its inflammation and has been recently involved
in insulin resistance of adipocytes (Regazzetti et al., 2009; Wood
et al., 2009).
In this review, we will first describe the major mediators that
link the excess of nutrients to the production of inflammatory
cytokines, focusing on pattern-recognition receptors (PRRs). We
will then discuss the intracellular signaling pathways activated
by inflammatory mediators and involved in the desensitization
of insulin signaling. We will also discuss whether and how the
blockade of these mechanisms could improve insulin sensitivity.
IMMUNE SENSORS LINKING NUTRITIONAL STRESS TO
OBESITY-INDUCED INFLAMMATION AND INSULIN
RESISTANCE
TOLL-LIKE RECEPTORS
Toll-like receptors (TLR) belong to the family of PRRs and play a
crucial role in innate immunity by their ability to sense pathogens
through the pathogen-associated molecular patterns (PAMPs)
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and to detect tissue injury through the danger-associated molec-
ular patterns (DAMPs) (Mogensen, 2009). TLRs 1/2/4/5/6/11 are
plasma membrane proteins whereas TLRs 3/7/8/9 are present in
intracellular compartments. Microbial components induce the
activation of the TLR signaling through a MyD88 (myeloid dif-
ferentiation factor)-dependent pathway, except for TLR3, lead-
ing to the activation of the transcription factors NF-κB and
AP-1 and the production of inflammatory cytokines. Mitogen-
activated protein kinases including extracellular signal-regulated
kinases (ERK1/2), JNK, and p38 are also activated by TLRs
engagement. TLR3 and TLR4 activation also induces an IFN-β
response through a MyD88-independent but TRIF (TIR domain-
containing adaptor inducing interferon)-dependent pathway
(Mogensen, 2009).
Among the different members of the TLR family, several
groups have reported a role for TLR2, TLR4 in inflammation and
insulin resistance during obesity (Fresno et al., 2011; Könner and
Brüning, 2011). Most of the studies focused on TLR4 which is
expressed in macrophages, dendritic cells but also in adipocytes,
hepatocytes, muscles, and in the hypothalamus. TLR4 expres-
sion is increased in obese mice and obese and diabetic patients
and negatively correlates with insulin sensitivity (Könner and
Brüning, 2011). Recently it has been proposed that during obe-
sity, metabolic endotoxemia contributes to the development of
inflammation and metabolic disorders through the activation
of TLR4 in metabolic tissues (Figure 1). Metabolic endotoxemia
is defined as a moderate increase in circulating lipopolysaccha-
ride (LPS) from Gram-negative bacteria and it develops owing
to alterations in the composition of gut microbiota and to an
increase in gut permeability (Cani and Delzenne, 2009; Burcelin
et al., 2011). Further, high-fat diet could also enhance the translo-
cation of live Gram-negative bacteria from the gut to the adipose
FIGURE 1 | Major Patterns-Recognition Receptors involved in
obesity-induced inflammation. In obesity, the moderate increase in LPS
derived from gram-negative commensal bacteria activates TLR4 (Toll-like
receptors). TLR2 and NOD1/2 (Nucleotide Oligomerization Domain) could
be activated by peptidoglycan, lipoproteins, and lipoteichoic acid from
gram-negative or -positive commensal bacteria. In addition, nutrients such
as saturated fatty acids and their metabolites ceramides could interact
with TLR4 or could indirectly activate this receptor through the production
of DAMPs such as HMGB1. TLR2 could also be a receptor for saturated
fatty acids. Following activation of these receptors, inflammatory cytokines
are produced. Among them, IL-1β and IL-18 should be processed in their
mature forms by the NLRP3 inflammasome composed of NLRP3, ASC,
and caspase-1. ROS production in response to a high level of fatty acids,
ceramides, or glucose could trigger the association between TXNIP and
NLRP3 leading to the activation of caspase-1 in the inflammasome
complex.
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tissue, a process that is dependent, at least partly, on CD14
that acts as a co-receptor with TLR4 to sense LPS (Amar et al.,
2011).
Saturated fatty acids are other potential ligands of TLR4 both
in adipocytes and macrophages leading to the production of
inflammatory cytokines and also ceramides (Shi et al., 2006b;
Radin et al., 2008; Fresno et al., 2011; Könner and Brüning, 2011)
(Figure 1). TLR4 also mediates the cross-talk between adipocytes
and macrophages induced by fatty acids (Suganami et al., 2007b).
However, a direct binding of saturated fatty acids to TLR4 has
been recently challenged due to LPS contamination (Erridge and
Samani, 2009). It is thus possible that saturated fatty acids indi-
rectly interact with TLR4 through fetuin A (Pal et al., 2012).
Alternatively, fatty acids might activate TLR4 signaling through
the production of endogenous DAMPs such as HMGB1 (High-
Mobility Group Box1) and/or through ceramides production
(Fischer et al., 2007; Li et al., 2011) (Figure 1).
The in vivo pathophysiological importance of TLR4 in obesity-
induced inflammation and insulin resistance was investigated
by using mice deficient in TLR4 signaling owing to invalida-
tion of TLR4 (TLR4−/− mice) or to a loss-of-function mutation
in the Tlr4 gene (C3H/HeJ and C57BL/10ScN) (Table 1). The
different studies have reported a mild reduction in inflamma-
tion in adipose tissue and liver or in the vasculature (Shi et al.,
2006b; Kim et al., 2007; Poggi et al., 2007; Suganami et al.,
2007a; Tsukumo et al., 2007; Li et al., 2011; Orr et al., 2012;
Ye et al., 2012). The lower inflammation in adipose tissue was
linked to a decrease in macrophage infiltration or to a change in
macrophage polarization toward aM2 anti-inflammatory pheno-
type (Shi et al., 2006b; Tsukumo et al., 2007; Davis et al., 2008;
Orr et al., 2012). Reduction in inflammation in liver Kupffer cells
and in liver parenchymal cells (Li et al., 2011; Ye et al., 2012) was
associated with a decrease in hepatic steatosis or with a reduction
in the progression from steatosis to non-alcoholic steatohepati-
tis (Poggi et al., 2007; Tsukumo et al., 2007; Radin et al., 2008; Li
et al., 2011; Orr et al., 2012; Ye et al., 2012). In contrast, contra-
dictory results have been obtained concerning the development
of obesity. Some studies have reported that C3H/HeJ, 10ScN, or
male TLR4−/− mice gained less weight on a high-fat diet than
their respective controls (Tsukumo et al., 2007; Davis et al., 2008;
Radin et al., 2008; Saberi et al., 2009; Orr et al., 2012). This
phenotype could be related to a protection against diet-induced
leptin or insulin resistance in the hypothalamus in the absence of
a functional TLR4 signaling (Kleinridders et al., 2009; Milanski
et al., 2009; Könner and Brüning, 2011). However, other stud-
ies have described a higher feeding efficiency of the C3H/HeJ
mice with increased adipose tissue mass and adipocyte hyper-
trophy (Poggi et al., 2007), an increase in body weight gain and
Table 1 | Phenotype of the different TLR4-deficient mice fed with a high-fat diet.
Genotype % Fat Body Weight Whole-Body Food Adipose ATM Adipose Steatosis
in diet gain IS Intake Tissue Tissue IS
inflammation
Tsukumo et al. C3H/HeJ 55 ↓ ↑ = ↓ ↓ ↑ ↓
Poggi et al. C3H/HeJ 45 = = ↓ ↓ = ↑ ↓
Suganami et al. C3H/HeJ 60 = ↑ ND ↓ = ND ND
Davis et al. 10 ScN 60 ↓ ↑ ND ↓ ± ↓ ND ND
Radin et al. 10 ScN 45 ↓ = ↓ ND ND ND ↓
Li et al. 10 ScN 60 ↓ = ND ND ND ↓
Shi et al. TLR4−/− F 60 ↑ ↑ ↑ ↓ ↓ ND ND
Shi et al. TLR4−/−M 60 = = = ↓ ND ND ND
Orr et al. TLR4−/− 45 ↓ = ↓ ↓ ± ↑ M2 ND ↓
Saberi et al. TLR4−/− No data ↓ ND ND ND ND ND ND
Ding et al. TLR4−/−LDLR−/− 35.5 = = = = = ND ND
Kim et al. TLR4−/− 60 = ND ND ND ND ND ND
Saberi et al. BMT-10ScN No data = ↑ = ↓ ↓ ↑ ↓
Orr et al. BMT-TLR4−/− 45 = = ND ↓ ↑ M2 ND =
Coenen et al. BMT-TLR4−/− 41 = = ND = = ND ND
C3H/HeJ: Mice harboring a spontaneous missense mutation in the third exon in the Tlr4 gene leading to a loss-of-function of TLR4.
10ScN: Mice that display a spontaneous mutation resulting in 7 kb deletion in the Tlr4 gene that results in absence of both mRNA and protein expression.
TLR4−/−: Mice with a knockout of the Tlr4 gene. F female. M male.
BMT-10ScN: Transplantation of bone marrow from 10ScN mice into C57BL6 mice.
BMT-TLR4−/−: Transplantation of bone marrow from TLR4−/−mice into C57BL/6 mice (Orr et al) or into agouty (Ay /a)/LDL-receptor deficient mice (Ay /a;Ldlr−/−)
(Coenen et al.).
IS: Insulin Sensitivity.
ATM: Adipose tissue macrophages.
M2: macrophages with a M2 anti-inflammatory polarization.
ND: not determined in the study.
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adipose tissue mass in female TLR4−/− mice (Shi et al., 2006b) or
no protection against obesity in male TLR4−/− mice (Shi et al.,
2006b; Kim et al., 2007). Themajority of the studies have reported
a reduction in the insulin resistance, at least in adipose tissue
and liver (Shi et al., 2006b; Suganami et al., 2007a; Tsukumo
et al., 2007; Poggi et al., 2007; Davis et al., 2008). However, some
of them, mainly concerning male TLR4−/−, did not show any
improvement in whole-body insulin sensitivity (Shi et al., 2006b;
Radin et al., 2008; Ding et al., 2012; Orr et al., 2012).
Different studies have investigated the consequences of TLR4
invalidation specifically in immune cells by transplantation of
bonemarrow fromTLR4-deficientmice into wild-type recipients.
In one study, mice developed obesity but with less inflammation
and insulin resistance in adipose tissue and liver and no change
in muscles (Saberi et al., 2009). In contrast, two other stud-
ies using the same experimental strategy but in different genetic
backgrounds, failed to observe any improvement in insulin resis-
tance despite a reduction in adipose tissue inflammation and/or
a shift in adipose tissue macrophage polarization toward a M2
anti-inflammatory state (Coenen et al., 2009; Orr et al., 2012).
In summary, the consequences on weight gain and insulin
resistance are different depending on the genetic background, the
sex of the mice, the duration, and the lipid composition of the
diet. In this regard, the percentage of saturated lipids in the diet
could be important since the protection against insulin resistance
seemed to occur selectively when the diet contained a high level
of saturated lipids (Davis et al., 2008). It remains to be deter-
mined whether the activation of TLR4 signaling by a saturated
fat diet is due to a direct action of fatty acids on TLR4 or to
an indirect effect through the production of endogenous DAMPs
or through the modification of the gut microbiota leading to an
increase in circulating LPS. Further, clarification is needed for the
respective contribution of TLR4 signaling in hematopoietic vs.
non-hematopoietic compartment to the development of insulin
resistance. Of note, the analysis of the metabolic phenotype of the
TLR4-deficient mice could be complicated due to the potential
compensatory increase in TLR2 expression (Ding et al., 2012).
TLR2 detects lipoproteins, lipoteichoic acid, and peptidogly-
can from gram-positive bacteria and dimerizes with TLR1 and
TLR6 (Mogensen, 2009). TLR2 has a broad pattern of expres-
sion and besides its expression in immune cells, is also expressed
in insulin sensitive cells and islets (Ehses et al., 2010). A role
for TLR2 in the metabolic complications of obesity was sug-
gested by its increased level in different metabolic tissues of obese
mice and patients and in circulating monocytes of type 2 dia-
betic patients (Fresno et al., 2011; Könner and Brüning, 2011).
Like TLR4, TLR2 could be a sensor for saturated fatty acids
mediating their pro-inflammatory effects in adipose tissue and
macrophages and participating in the development of insulin
resistance in cultured myotubes or adipocytes (Fresno et al., 2011;
Könner and Brüning, 2011). However, as for TLR4, a direct acti-
vation of TLR2 by saturated fatty acids has been questioned owing
to possible contamination by LPS (Erridge and Samani, 2009).
Thus, both TLR4 and TLR2 could participate in the sensing of
abnormal levels of nutrients, especially fatty acids and in the
detection of gut microflora modification in obesity (Figure 1).
Cooperation between these two TLRs might be involved since
TLR4 activation increases the synthesis of TLR2 in adipocytes.
This overlapping function could explain the similar metabolic
phenotype of TLR4 and TLR2 deficientmice. Indeed, invalidation
of TLR2 improved diet-induced insulin resistance and inflam-
mation of adipose tissue, liver, or muscles (Caricilli et al., 2008;
Kuo et al., 2011; Ehses et al., 2010 #3013, Himes and Smith,
2010 #3010). Further, TLR2 signaling is involved in diet-induced
pancreatic islet inflammation and beta-cell dysfunction (Ehses
et al., 2010). TLR2 knockout mice have also a reduced adipos-
ity (Ehses et al., 2010; Himes and Smith, 2010; Kuo et al., 2011)
suggesting that the lack of TLR2 signaling could decrease lipid
uptake or increase lipid oxidation in different tissues. Whether
the effect of TLR2 activation on lipid metabolism is direct or
the consequence of an inflammatory state remains to be clari-
fied. However, the reported interaction between activated TLR2
and CD36, a transporter of fatty acids, supports a role for TLR2
signaling in fatty acids uptake in metabolic tissues (Triantafilou
et al., 2006).
Although the findings discussed above support a protective
role of TLR2 inactivation in the context of obesity, a recent
study reported that TLR2 knockout mice had a phenotype rem-
iniscent of metabolic syndrome even on low-fat diet. In this
setting, it was demonstrated that the gut microbiota was respon-
sible for the development of insulin resistance (Caricilli et al.,
2011). This finding illustrates the concept that complex inter-
actions between environment, gut microbiota, and the genetic
of the host drive the metabolic phenotype (Nicholson et al.,
2012). In this regard, a specific environmental condition and the
innate immune system may have shaped a harmful gut micro-
biota that overcomes the protective effect of the genetic deficiency
in TLR2. Alternatively the loss of TLR in immune cells may alter
gut microbiota leading to the development of inflammation, obe-
sity, and insulin resistance as described for mice lacking TLR5
(Vijay-Kumar et al., 2010), a TLR highly expressed in the intesti-
nal mucosa and involved in the detection of bacterial flagellin
(Mogensen, 2009).
INFLAMMASOME AND NOD
Nucleotide oligomerization domain (NOD) 1 and 2 are intracel-
lular proteins that recognize cell wall peptidoglycanmoieties from
gram-negative or gram-positive bacteria, respectively (Mogensen,
2009). NOD proteins have recently emerged as immune sensors
involved in inflammation-induced insulin resistance (Figure 1).
Peptidoglycan-induced activation of NOD1 in adipocytes or hep-
atocytes (Schertzer et al., 2011; Zhao et al., 2011) and NOD2
in muscle cells (Tamrakar et al., 2010) trigger insulin resis-
tance through the production of inflammatory mediators and
the activation of MAP kinases signaling leading to desensi-
tization of IRS1 function. Injection of specific NOD1 ligand
in mice promoted adipose tissue inflammation and induced
whole-body insulin resistance with a strong decrease in insulin
action in the liver. NOD2 ligand injection caused a milder
insulin resistance and preferentially in muscles (Schertzer et al.,
2011). NOD1-deficient mice, but not NOD2, were protected
against glucose intolerance and diabetes induced by a high-fat
diet (Amar et al., 2011). These studies demonstrate the abil-
ity of NOD activation to induce insulin resistance and support
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the implication of NOD1 in the control of metabolic diseases
through the sensing of components from gram-negative bacteria
(Figure 1).
Inflammasomes are multi-protein complexes composed of
three proteins: the nucleotide-binding domain leucine-rich repeat
(NLR) protein, the adaptor protein ASC (apoptosis-associated
speck-like protein containing a CARD) and the caspase-1. Four
different inflammasomes have been identified so far namely
NLRP1, NLRP3, NLRC4, and AIM2. Pathogen and danger-
associated signals activate inflammasomes leading to the pro-
cessing of IL-1β and IL-18 by caspase-1 (Mogensen, 2009). It
is recognized that IL-1β is one of the main cytokines impli-
cated in the desensitization of insulin signaling (Lagathu et al.,
2006; Jager et al., 2007) and its genetic invalidation protects
mice against diet-induced insulin resistance (Stienstra et al., 2010;
Wen et al., 2011). Pharmacological inhibition of IL-1β signaling
by the IL-1 receptor antagonist anakinra, mitigates inflamma-
tion, and improves glycemic control in type 2 diabetic patients
(Larsen et al., 2007). With this inmind, several groups have inves-
tigated the implication of inflammasome activation in insulin
resistance.
The expression of NLRP3 and caspase-1 is increased in adi-
pose tissue of obese mice, overweight subjects, or obese indi-
viduals with type 2 diabetes (Stienstra et al., 2010; Koenen
et al., 2011; Vandanmagsar et al., 2011). The identity of cells
within the adipose tissue, in which the NLRP3 inflammasome
is activated, remains controversial. Two studies reported an
expression and activation mainly in adipose tissue macrophages
with a low expression in adipocytes whereas Stienstra et al.
found an important contribution of adipocytes (Stienstra et al.,
2010; Vandanmagsar et al., 2011; Wen et al., 2011). However,
invalidation of different components of the NLRP3 inflamma-
some (NLRP3, ASC, caspase-1) univocally protected the mice
against high-fat diet-induced inflammation and insulin resis-
tance. This phenotype was associated with a reduced expression
of IL-1β in adipose tissue and a reduced level of circulating
IL-18 (Stienstra et al., 2010; Vandanmagsar et al., 2011; Wen
et al., 2011). The lack of the NLRP3 inflammasome had con-
sequences on the subset of immune cells within the adipose
tissue. The number of M2 anti-inflammatory macrophages was
increased in subcutaneous adipose tissue (SAT) and the activa-
tion of pro-inflammatory macrophages was dampened in vis-
ceral adipose tissue (VAT). In parallel, the number of naive
CD4+ and CD8+ T cells was increased in SAT and the amount
of effector memory CD4+ and CD8+ T cells was decreased
in VAT (Vandanmagsar et al., 2011). These findings suggest a
model whereby the NLRP3 inflammasome-dependent produc-
tion of IL-1β and IL-18 by adipose tissue macrophages favors
macrophage-T cell activation leading to a sustained inflamma-
tion of adipose tissue (Vandanmagsar et al., 2011). Besides its
role in the control of adipose tissue inflammation, inflamma-
some activation in adipocytes could limit energy expenditure,
fat oxidation, and adipogenesis as revealed by the phenotype of
the caspase1−/− mice (Stienstra et al., 2010, 2011). In addition
to adipose tissue, activation of NLRP3-inflammasome in other
tissues such as pancreatic islets has been reported (Zhou et al.,
2010).
These findings strongly support a model whereby dan-
ger signals generated in obesity are detected by the NLRP3-
inflammasome that in turn promotes inflammation and the
dysfunction of different organs involved in the control of glucose
and lipid homeostasis (Figure 1). The identity of the danger sig-
nals that activate the NLRP3 inflammasome in obesity remains
ill-defined. However, the observation that the NLRP3 inflam-
masome is activated by fatty acids and ceramides suggests that
the lipotoxic environment in obesity might trigger its activa-
tion (Vandanmagsar et al., 2011; Wen et al., 2011). However, the
NLRP3 inflammasome can be activated by other molecules such
as ATP, glucose, oxidized LDL, uric acid, and crystals of choles-
terol. Since all of them are elevated in obesity, their respective
contributions to the activation of inflammasome deserve fur-
ther investigation. The common feature of these danger signals
is their ability to increase ROS production that is prerequisite
for NLRP3 inflammasome activation (Tschopp and Schroder,
2010). Thus, the activation of NLRP3 inflammasome in obe-
sity might be related to the oxidative stress that develops in the
different metabolic tissues. How NLRP3 inflammasome is acti-
vated by ROS is not completely understood but the thioredoxin-
interacting protein (TXNIP) has recently emerged as a potential
link with the demonstration of its binding with NLRP3 in a ROS
sensitive manner leading to NLRP3 inflammasome activation
(Zhou et al., 2010) (Figure 1). This function might explain the
similar phenotype between TXNIP- and NLRP3-deficient mice
when fed a high-fat diet (Zhou et al., 2010). Further TXNIP
might also connect organelle stress, such as reticulum endoplas-
mic stress, to NLRP3 inflammasome activation (Oslowski et al.,
2012).
All together, these findings render the NLRP3 inflammasome
as an attractive pharmacological target against the complications
of obesity. In this multi-proteins complex, the easiest target is the
caspase-1 since inhibitors already exist. The caspase-1 inhibitor
Pralnacasan reduced body weight and improved insulin sensi-
tivity of genetically obese ob/ob mice (Stienstra et al., 2010).
However, one important caveat for the treatment of a chronic
disease such as diabetes is that caspase-1 is involved in differ-
ent inflammasome complexes and its inhibition may reduce the
ability to fight infection.
Despite the potential role of the NLRP3 inflammasome in
obesity-induced inflammation and insulin resistance, it remains
to determine whether its activation is a primary event in the
disease that drives the inflammation. Further, the relative contri-
bution of NLRP3 inflammasome to the development of inflam-
mation in the metabolic tissues and in the different subset of
cells of these tissues should be clarified. The role of other inflam-
masome complexes also deserves investigation since ablation of
NLRP3 markedly reduced but did not totally abrogate caspase-1
activation in adipose tissue or liver of obese mice (Vandanmagsar
et al., 2011). Finally, other caspase-1 substrates besides IL-1β and
IL-18might be involved in the deleterious effect of inflammasome
activation on metabolic control. In this regard, the transcription
factors SREBPs are activated by caspase-1(Gurcel et al., 2006)
and it was recently shown that SREBP-1a regulated the expres-
sion of inflammasome components in macrophages (Im et al.,
2011). Thus, a feed-forward loop involving caspase-1 activation
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and SREBP might link lipid metabolism to the inflammasome
activation in obesity.
In conclusion, it is now recognized that the immune sen-
sors described above (TLR, NOD, inflammasome) and others
such as the pathogen-sensing kinase (PKR) (Nakamura et al.,
2010) participate in the development of the metabolic inflam-
mation. As recently discussed by Gregor and Hotamisligil in
an outstanding review (Gregor and Hotamisligil, 2011), it is
possible that in obesity the levels of nutrient intake may rise
enough to stimulate pathogen- and danger-sensing pathways
ultimately leading to the activation of immune cells in the dif-
ferent metabolic tissues. In other words, the organism, in over-
feeding situation, recognizes the nutrients as harmful biological
molecules and activates pathways that are usually engaged by
pathogen or endogenous danger signals. In addition, modifica-
tion of the gut microbiota and of the intestinal permeability
in obesity may fuel the organism with inflammatory molecules
such as LPS and other bacterial antigens or favor the transloca-
tion of commensal bacteria within metabolic tissues (Cani and
Delzenne, 2009; Amar et al., 2011; Nicholson et al., 2012). As
a consequence, inflammatory cytokines are overproduced and
they activate different signaling pathways in metabolic cells that
desensitize insulin signaling and alter the expression of pro-
teins involved in glucose transporter trafficking (Kaddai et al.,
2009).
INFLAMMATORY SIGNALING PATHWAYS INVOLVED IN
THE DESENSITIZATION OF INSULIN ACTION
THE SOCS PROTEINS
The Suppressor of cytokine signaling (SOCS) protein family also
named Janus family kinase-binding (JAB) proteins or SSI (signal
transducer and activator of transcription induced Stat inhibitor)
includes eight members (SOCS1–7 and CIS), which possess a SH2
domain, and a SOCS-box domain controlling the degradation
of interacting proteins. They are induced by several inflamma-
tory cytokines and are involved in a negative feedback loop
leading to the termination of cytokines action. At the molecu-
lar level, the SOCS proteins interact with the tyrosine kinases
Janus-activated kinases (JAK) or directly with the receptor of
some cytokines, thus blocking the tyrosine phosphorylation of
the transcription factors STAT for review see Lebrun and Van
Obberghen (2008). Several cellular studies have demonstrated
that SOCS negatively regulate the signaling pathway of hormones
including leptin and insulin. In this regard, SOCS3 is induced by
leptin and insulin and is involved in a negative feedback loop and
in a cross-down regulation (Emanuelli et al., 2000; Lebrun and
Van Obberghen, 2008; Benomar et al., 2009). SOCS1, SOCS6,
and SOCS7 are also involved in the desensitization of insulin
signaling. SOCS3 inhibits insulin signaling by a direct binding
through its SH2 domain with the juxtamembrane phosphotyro-
sine 960 on the insulin receptor, thus preventing the interaction
of IRS1 and 2 with the receptor (Figure 2). SOCS1 interacts
with the catalytic domain of the insulin receptor which con-
tains an interaction motif for IRS2, blocking thus more selectively
the tyrosine phosphorylation of IRS2. SOCS1 and SOCS6 also
inhibit the tyrosine kinase activity of the insulin receptor. It has
also been shown that SOCS proteins interact with the tyrosine
phosphorylated IRS1 and IRS2 resulting in their ubiquitination
and degradation by the proteasome (Lebrun and Van Obberghen,
2008) (Figure 2).
In obesity, inflammation leads to an up-regulation of SOCS
proteins in hypothalamus, liver, muscles, and adipose tissue
(Rieusset et al., 2004; Lebrun and Van Obberghen, 2008). A
causal role for the up-regulation of SOCS proteins in the devel-
opment of insulin resistance has been investigated in metabolic
tissues. Overexpression of SOCS1 or SOCS3 in mouse liver or
adipose tissue reduced the expression of IRS1 or IRS2 as well as
their tyrosine phosphorylation induced by insulin. As a conse-
quence insulin resistance developed in those tissues, as well as
systemic insulin resistance for the overexpression in liver (Ueki
et al., 2005; Shi et al., 2006a). Unexpectedly, overexpression of
SOCS3 in adipose tissue protected the mice against systemic
insulin resistance when fed a high-fat diet owing to a decrease
in adipocyte hypertrophy (Shi et al., 2006a). Overexpression of
SOCS3 in muscle exacerbated diet-induced obesity and insulin
resistance but this effect was not due to a decreased insulin signal-
ing but to an alteration in muscle integrity leading to a reduction
in locomotor activity and energy expenditure (Lebrun et al.,
2009).
The inhibition of SOCS proteins might thus be useful to
prevent the development of obesity-induced insulin resistance.
In agreement with such a possibility, heterozygous SOCS3
(SOCS3+/−) mice or mice with targeted invalidation of SOCS3
in the central nervous system (CNS) were protected against diet-
induced obesity and associated insulin resistance (Howard et al.,
2004; Mori et al., 2004; Kievit et al., 2006). This phenotype
was explained by increased leptin sensitivity and possibly by an
effect on insulin action for the SOCS3+/− mice (Howard et al.,
2004). In the same way, targeted invalidation of SOCS3 in adi-
pose tissue or in muscles protected mice against obesity-induced
insulin resistance (Jorgensen et al., 2012; Palanivel et al., 2012).
SOCS7-deficient mice also displayed improved glucose tolerance
and insulin sensitivity (Banks et al., 2005). However, several
considerations should be taken into account before inhibit-
ing SOCS proteins for therapeutic purpose. First, some SOCS
proteins positively regulate insulin action as demonstrated by
the improved insulin sensitivity of SOCS6-overexpressing mice
(Li et al., 2004). Second, given that SOCS proteins negatively
regulate the signaling of inflammatory cytokines, their chronic
inhibition might exacerbate inflammation that could counterbal-
ance its beneficial effect on insulin sensitivity. This dual action
of SOCS proteins is well-illustrated by differential effects of
short- and long-term invalidation of SOCS1 or SOCS3 in liver.
Short-term invalidation by antisense oligonucleotides in obese
and diabetic db/db mice improved hepatic steatosis with a mild
reduction in insulin resistance (Ueki et al., 2005). In contrast,
while targeted deletion of SOCS3 in liver-enhanced liver insulin
sensitivity on chow diet, it accelerated the onset of high-fat diet-
or age-induced insulin resistance with an increased inflamma-
tion in liver (Torisu et al., 2007; Sachithanandan et al., 2010).
This dual action is not restricted to SOCS3, since SOCS1 in
immune cells limited the metabolic inflammation in liver and
perhaps adipose tissue (Sachithanandan et al., 2011). Thus,
the beneficial effect of SOCS1-deletion on insulin sensitivity
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FIGURE 2 | Inhibition of insulin signaling pathway by SOCS1 and
SOCS3. SOCS1 and SOCS3 are induced by cytokines and involved in a
negative feed-back loop. SOCS1 and SOCS3 also inhibit insulin signaling by
different mechanisms. They interfere with the binding between the insulin
receptor and IRS1/2 proteins. SOCS1 also inhibits the tyrosine kinase activity
of the insulin receptor. Both SOCS1 and SOCS3 can interact with the
tyrosine-phosphorylated IRS proteins leading to their degradation by the
proteasome. The resulting effect is a decrease in the insulin-induced
activation of the IRS1/2-PI3K-PKB axis leading to a reduction in the metabolic
effects of insulin.
was only visible when SOCS1-deficient mice were crossed with
interferon-gamma- or RAG2-deficient mice to limit inflamma-
tion. Of note, this beneficial effect was seen on chow diet
(Jamieson et al., 2005; Emanuelli et al., 2008b) but was lost on
a high-fat diet when the inflammation is enhanced (Emanuelli
et al., 2008b). Further, SOCS2-deficient mice were protected
against diet-induced hepatic steatosis probably due to an increase
in the lipid mobilizing effect of growth hormone. However,
this beneficial effect was overridden by a hyperproduction of
inflammatory mediators by the resident macrophages leading
to a higher level of inflammation in liver and adipose tis-
sue and the worsening of insulin resistance (Zadjali et al.,
2012).
In summary, it appears to date that SOCS3 is mainly involved
in the regulation of energy balance through the down-regulation
of leptin signaling whereas several SOCS such as SOCS1/3/6/7 are
involved in the regulation of the insulin sensitivity. Since SOCS
proteins contribute to the development of diet-induced obesity
and insulin resistance, their targeting could be open new avenues
for the treatment of metabolic disorders. However, careful exam-
ination of the balance between pro-inflammatory and insulin
sensitizing effects of future inhibitors of SOCS proteins will be
needed.
THE IKKβ/NF-κB AND JNK PATHWAYS IN INFLAMMATORY CYTOKINES
PRODUCTION AND INSULIN RESISTANCE
The activity of both IκB-kinase β (IKKβ) and JNK is elevated
in metabolic tissues in obesity, and these kinases are important
nodes in the production of inflammatory mediators and in the
desensitization of insulin signaling (Tanti and Jager, 2009; Solinas
and Karin, 2010; Donath and Shoelson, 2011). JNK and IKKβ
are activated downstream of immune sensors such as TLRs and
participate in the production of inflammatory cytokines via the
transcription factors AP-1 and NF-κB respectively (Figure 3).
Many of the produced inflammatory cytokines are able to activate
these two kinases leading to a feed-forward amplification loop
(Donath and Shoelson, 2011; Gregor and Hotamisligil, 2011).
Another important activator of these kinases is the endoplasmic
reticulum (ER) stress (Figure 3).
ER stress occurs when the synthesis capacity of the ER is
exceeded. In this case, the unfolded protein response (UPR) is
activated in order to restore ER homeostasis. Three pathways are
involved in the UPR, namely PERK (PKR-like eukaryotic initia-
tion factor 2a), IRE-1 (inositol requiring enzyme 1), and ATF6
(activating transcription factor 6) pathways. If these mechanisms
fail to restore proper ER homeostasis, cells undergo apoptosis
(Xu et al., 2005). In a pioneer study, Hotamisligil and colleagues
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FIGURE 3 | Serine kinases involved in obesity-induced inflammation
and insulin resistance. In obesity, a network of serine kinases is activated
including IKKβ, JNK, and ERK1/2. JNK and IKKβ are activated downstream
of pattern-recognition receptors (PRRs) such as TLRs or by ER stress.
IKKβ is also involved in the activation of the Tpl2/ERK pathway. These
pathways participate in the production of inflammatory cytokines via the
transcription factors AP-1 and NF-κB. Many of the produced inflammatory
cytokines are able to activate these kinases leading to a feed-forward
amplification loop. JNK and ERK1/2 are involved in the desensitization of
insulin signaling through phosphorylation of IRS1/2 on inhibitory serine
sites (SerP). IKKβ can directly phosphorylate IRS1/2 on serine sites but can
also act indirectly through activation of mTORC1/S6 kinase. Over-activation
of the mTORC1/S6K pathway could promote ER stress leading to an
amplification loop.
(Ozcan et al., 2004) have demonstrated that ER stress developed
in liver and adipose tissue during obesity owing to nutrient over-
load and participated in the onset of insulin resistance. Several
recent reviews have discussed in details the mechanisms link-
ing ER stress to obesity-induced inflammation, insulin resistance,
and alterations in tissue metabolism (Cnop et al., 2011; Gregor
and Hotamisligil, 2011; Flamment et al., 2012). The activation of
IKKβ/NF-κB and JNK by the IRE-1 arm of the UPR is one of these
mechanisms (Gregor and Hotamisligil, 2011).
At the molecular level, one important mechanism by which
IKKβ and JNK attenuate insulin signaling is the phosphoryla-
tion of IRS proteins on inhibitory serine phosphorylation sites
(Figure 3). The mechanism by which IRS phosphorylation reg-
ulates insulin signaling is complex and described in details in
recent reviews (Gual et al., 2005; Boura-Halfon and Zick, 2009;
Tanti and Jager, 2009; Copps and White, 2012). In physiologi-
cal condition, insulin induces a time-controlled phosphorylation
of both positive and inhibitory serine sites in IRS1 and IRS2
in order to ensure the fine tuning of IRS tyrosine phosphoryla-
tion that is necessary for the propagation of insulin action (Tanti
and Jager, 2009; Copps and White, 2012). Since our pioneer
study (Tanti et al., 1994), it is now admitted that during obe-
sity, activation of inflammatory, and stress kinases such as JNK
and IKK is responsible for an uncontrolled phosphorylation of
IRS on inhibitory serine sites resulting in a decrease in IRS tyro-
sine phosphorylation and a desensitization of insulin signaling
(Boura-Halfon and Zick, 2009; Tanti and Jager, 2009). It is note-
worthy that JNK seems more involved in the direct IRS serine
phosphorylation than IKKβ (Tanti and Jager, 2009). IKKβ acti-
vation could promote IRS1 serine phosphorylation through acti-
vation of TSC1/TSC2/mTORC1/S6 Kinase-1 pathway leading to
inhibitory IRS1 serine phosphorylation by S6K1 (Lee et al., 2008).
Of note, activation of mTORC1 by IKKβ could be also involved
in feed-forward mechanism induced by inflammatory cytokines
to promote ER stress since over-activation of mTORC1 has
been linked to the development of ER stress (Ozcan et al., 2008)
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(Figure 3). In addition, activation of the IKKβ/NFκB pathway
increases the expression of PTP1B, a tyrosine phosphatase that
dephosphorylates IRS1 (Zabolotny et al., 2008).
Several in vivo studies in mice have demonstrated the impor-
tance of the IKKβ/NF-κB and JNK pathways in the develop-
ment of insulin resistance (Figures 4, 5). Heterozygous IKKβ and
whole-body JNK1-deficient mice were partially protected against
diet-induced insulin resistance (Yuan et al., 2001; Hirosumi et al.,
2002). JNK2 could also play a role in insulin resistance but to a
lesser extent (Tuncman et al., 2006). A cell-autonomous mech-
anism that involves the negative regulation of IRS1 function
by serine phosphorylation was implicated in the regulation of
insulin resistance induced by JNK1 and possibly by IKKβ dur-
ing obesity (Hirosumi et al., 2002; Sabio et al., 2010b). IKKβ
haplo-insufficiency or JNK1invalidation could also reduce the
pro-inflammatory effect of high-fat diet. In this regard, mice
lacking IKKβ or JNK1 in immune cells were partially protected
against obesity-induced inflammation (Arkan et al., 2005; Solinas
et al., 2007; Vallerie et al., 2008). However, if the protection
against systemic insulin resistance was obvious for IKKβ deletion
(Arkan et al., 2005), contradictory results were reported for JNK1
invalidation (Solinas et al., 2007; Sabio et al., 2008; Vallerie et al.,
2008).
The picture that emerges is that activation of these pathways
in non-hematopoietic cells also participates in tissues inflam-
mation and local or systemic insulin resistance. However, the
consequences of IKKβ and JNK activation on the development
of insulin resistance could totally differ and depend on the site
of action, the level of expression and the impact on adiposity.
Indeed, the activation of IKKβ/NF-κB in hepatocytes-induced
liver inflammation and insulin resistance (Arkan et al., 2005; Cai
et al., 2005; Tamura et al., 2007; Wunderlich et al., 2008) and was
associated with a reduced ability of insulin to suppress neogluco-
genesis (Arkan et al., 2005) and with an increased production
of VLDL leading to the development of hypertriglyceridemia
(van Diepen et al., 2011). At the opposite of these findings, the
development of inflammation induced by a moderate IKKβ acti-
vation in adipose tissue and before the onset of obesity has been
shown to be protective against diet-induced insulin resistance
by limiting adipose tissue expansion and by increasing energy
expenditure (Jiao et al., 2012). Furthermore, in contrast to the
deleterious effect of IKKβ, the activation of JNK pathway in liver
FIGURE 4 | Consequences of the genetic manipulation of IKKβ on
the metabolic phenotype of mice. Constitutive activation of IKKβ
(CA IKKβ) in hepatocytes results in a deterioration of the insulin
sensitivity of lean mice. At the opposite constitutive activation of IKKβ
in adipocytes protects the mice against obesity and insulin resistance
when fed a high-fat diet. Study of heterozygote IKKβ mice (IKKβ+/−)
or of mice with a tissue specific inactivation of IKKβ in the central
nervous system (CNS), hepatocytes, myeloid cells, or muscles
demonstrates that activation of IKKβ/NF-κB pathway is a core
mechanism that connects metabolic inflammation and insulin resistance
in peripheral metabolic tissues, except muscles, and in the central
nervous system.
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FIGURE 5 | Metabolic phenotype of whole-body JNK1 knockout mice
and of conditional JNK1 knockout mice. Whole-body invalidation of
JNK1 protects mice against diet-induced obesity and insulin resistance.
Tissue-specific invalidation of JNK1 reveals that the lack of JNK1 in
adipose tissue, muscles, or CNS protects against the development of
obesity and/or insulin resistance. The lack of JNK1 in myeloid cells
decreases obesity-induced inflammation but the impact on insulin
resistance development is controversial. At the opposite, the lack of
JNK1 in the hepatocytes alters liver function suggesting a protective
role of JNK1.
seems to have a protective role since hepatocyte-specific invali-
dation of JNK1 led to the development of glucose intolerance,
insulin resistance, and liver steatosis even in lean mice (Sabio
et al., 2009). This finding was quite unexpected given that the
liver of obese whole-body JNK1-deficient mice was more insulin
sensitive with less inflammation. Thus, it is possible that the inhi-
bition of JNK1 in hepatocytes per se is detrimental whereas the
combined inhibition of JNK1 in hepatocytes and in other liver
cells of the liver has a protective effect. Further, organ to organ
communication, especially cross-talk between liver and adipose
tissue, could be another explanation since JNK1 invalidation in
adipose tissue ameliorated liver insulin sensitivity (Sabio et al.,
2008; Zhang et al., 2011). One important mediator of this cross-
talk could be the adipocytokines, especially IL-6, which altered
liver insulin sensitivity through induction of SOCS3 (Sabio and
Davis, 2010). The consequences of JNK1 or IKKβ activation in
muscles are also totally different. While inactivation of IKKβ in
cultured muscle cells markedly reduced cytokine-induced insulin
resistance (Austin et al., 2008), the study of mice with condi-
tional knockout of IKKβ in muscles argues against a major role
of muscular IKKβ activation in obesity-associated insulin resis-
tance (Rohl et al., 2004). Muscle-specific invalidation of JNK1
improved high-fat diet-induced muscles insulin resistance but
also led to an enhanced liver steatosis and to a mild increase in
inflammatory mediator expression in adipose tissue. The cross-
talk between these different organs was mediated by an increase in
circulating triglycerides owing to a reduction in lipoprotein lipase
expression in muscles (Sabio et al., 2010b). Systemic insulin sen-
sitivity was slightly improved in those mice suggesting that the
improved insulin sensitivity inmuscles was sufficient to overcome
the enhanced liver steatosis and adipose tissue inflammation.
However, it is possible that with age, a worsening in insulin
sensitivity develops.
Several evidences suggest that activation of IKKβ and JNK
pathways in the hypothalamus by over-nutrition contributes to
energy imbalance and weight gain in addition to their role in
the development of insulin resistance. At the molecular level,
ER stress that develops in hypothalamus owing to an oversup-
ply in nutriments activates the IKKβ/NF-κB pathway leading to
local SOCS3 expression that interferes with both insulin and
leptin signaling (Zhang et al., 2008). The mechanism by which
JNK1 activation in the nervous system regulates body mass is
different and complex. Two studies have revealed that invali-
dation of JNK1 in the nervous system markedly enhanced the
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production of thyroid hormones through the hypothalamic-
pituitary-thyroid axis leading to an increase in energy expenditure
and a protection against obesity (Belgardt et al., 2010; Sabio et al.,
2010a).
These studies support the idea that the over-activation of
IKKβ/NF-κB and JNK pathways is a core mechanism that con-
nects metabolic inflammation and insulin resistance both in
peripheral tissues and in the CNS. This central role highlights
IKKβ and JNK as potential pharmacological targets against the
development of insulin resistance. In this regard, Shoelson and
colleagues have shown that high-doses of salicylate and its deriva-
tive salsalate were able to inhibit IKKβ activity and to improve
insulin sensitivity in obese mice (Donath and Shoelson, 2011).
Importantly, recent proof of concept studies and clinical trials
in type 2 diabetic patients suggest that salsalate ameliorates glu-
cose tolerance through better insulin sensitivity, and/or via an
increased insulin secretion (Koska et al., 2009; Goldfine et al.,
2010). The consequences of the pharmacological targeting of JNK
have been studied only in mice. Competitive inhibitors of ATP
directed against JNK and specific small substrate-competitive
inhibitors of JNK displayed protective effects against diet-induced
insulin resistance and/or weight gain (Bogoyevitch and Arthur,
2008; Cho et al., 2008; Yang and Trevillyan, 2008). These results
suggest that IKKβ or JNK inhibitors could be interesting ther-
apeutic agents against insulin resistance and type 2 diabetes.
However, it should be kept in mind that IKKβ/NF-κB pathway
is a central regulator of immunity and that JNK pathway regu-
lates numerous physiologic processes. Chronic inhibition of these
pathways might thus have side effects and favor the emergence of
other pathologies.
THE EXTRACELLULAR SIGNAL-REGULATED KINASES IN OBESITY
DEVELOPMENT AND INSULIN RESISTANCE
The Extracellular signal-Regulated Kinases (ERK) 1/2 (also
known as p44 and p42 MAP kinase) are activated by several
growth factors but also by inflammatory cytokines. The activa-
tion of ERK1/2 requires the phosphorylation of both tyrosine
and threonine residues located in a TEY sequence. This phos-
phorylation is mediated by the MAP kinase kinase (MAP2K)
MEK. The activation of MEK also requires its phosphorylation
by MAP kinase kinase kinase (MAP3K). Depending on the stim-
uli, different MAP3Ks are engaged to phosphorylate MEK. The
activated ERK1/2 phosphorylates numerous substrates with ser-
ine or threonine residues close to a proline residue (Keshet and
Seger, 2010). The activity of ERK1/2 is increased in adipose tissue,
liver, and muscles of obese/diabetic patients or mice for review
see Tanti and Jager (2009). Several cellular studies have shown
that activation of ERK1/2 by diabetogenic factors-induced IRS1
serine phosphorylation. These phosphorylation events decrease
the interaction between IRS1 and the PI3K or inhibit the asso-
ciation between IRS1 and the insulin receptor and would thus
diminish the metabolic effects of insulin (Tanti and Jager, 2009).
This mechanism has relevant implications in human pathology
since basal ERK activity and IRS1 phosphorylation are abnor-
mally increased in primary muscle cells from type 2 diabetic
patients (Bouzakri et al., 2003). In addition, activation of the
ERK pathway by the inflammatory cytokines, especially IL-1β, in
adipocytes also induced a decrease in the transcription of IRS-
1 mRNA, leading to a decrease in insulin signaling and glucose
transport (Jager et al., 2007). ERK activation by inflammatory
cytokines could also indirectly promote insulin resistance by the
stimulation of adipocyte lipolysis and the release of free fatty acids
(Souza et al., 2003).
The contribution of ERK pathway in the development of obe-
sity and insulin resistance was first demonstrated by our study
of ERK1-deficient mice (Bost et al., 2005). Those mice were pro-
tected against obesity when fed a high-fat diet, because of a
decrease in adipogenesis and an increase in postprandial energy
expenditure. The lack of obesity was associated with a bet-
ter glucose and insulin tolerance compared to wild-type mice
(Bost et al., 2005). Conversely, over-activation of the ERK path-
way owing to deletion of the signaling adapter p62 resulted in
the development of mature-onset obesity and insulin resistance
with reduced energy expenditure and increased adipogenesis
(Rodriguez et al., 2006). This phenotype was probably due to the
over-activation of ERK1 rather than ERK2 since deletion of ERK1
in the p62−/− genetic background reversed the phenotype (Lee
et al., 2010). Those studies clearly highlighted the role of ERK1 in
the development of obesity but did not allow concluding whether
ERK1 could modulate the insulin sensitivity independently of its
effect on body weight. However, we have recently shown that
invalidation of ERK1 protected obese ob/ob mice against insulin
resistance and adipose tissue inflammation without any changes
in obesity (Jager et al., 2011). Another study also suggested that
inhibition of ERK had beneficial effects on insulin resistance inde-
pendently of an effect on body weight gain (Emanuelli et al.,
2008a).
The pharmacological targeting of ERK1/2 against insulin resis-
tance could have a series of drawbacks since they are involved
in numerous biological processes. A possible alternative choice
would be to target proteins which control ERK activity, specifi-
cally in response to inflammatory stresses which develop during
obesity. In this regard, interesting candidates could be specific
MAP3 kinases that are important in innate immune receptor
signaling to MAP kinase activation (Symons et al., 2006).
Among the different MAP3K that control ERK activity, our
team recently identified the kinase Tpl2 (Tumor progression
locus, MAP3K8) as a potential new player in adipose tissue dys-
function and inflammation (Jager et al., 2010). In immune cells,
Tpl2 plays an important role in the production of inflamma-
tory cytokines, especially TNFα (Dumitru et al., 2000), and it
is also involved in cytokines signaling downstream of innate
immunoreceptors (Gantke et al., 2011). The importance of Tpl2
in inflammation has been demonstrated by the resistance to endo-
toxin shock and the lack of TNF-α production by macrophages of
the Tpl2-deficient mice (Dumitru et al., 2000). Further, Tpl2 is
a critical regulator of pancreatic, lung, and bowel inflammation
in mice (Gantke et al., 2011). In non-stimulated cells, Tpl2 binds
in its inactive form to p105NF-κB and is activated by different
inflammatory stimuli through phosphorylation and degradation
of p105NF-κB induced by IKKβ (Gantke et al., 2011). Among
them, LPS, TNF-α, IL-1β, and CD40 are involved in obesity-
induced inflammation and insulin resistance (Poggi et al., 2009;
Tanti and Jager, 2009) suggesting a potential role for Tpl2 in this
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pathology. Recently, we found Tpl2 up-regulated in adipose tis-
sue of obese mice and patients. Tpl2 was involved in the lipolytic
effect the inflammatory cytokines and in the serine phosphory-
lation of IRS1 in adipocytes (Jager et al., 2010). Based on these
findings, one can hypothesize that the targeting of Tpl2 could
have beneficial effects in the context of obesity by reducing the
production of inflammatory cytokines by adipose tissue immune
cells and by blocking their deleterious effects in adipocytes. In
agreement, one recent study has shown that Tpl2 inactivation
protected the mice against insulin resistance with a reduction
in liver and adipose tissue inflammation (Perfield et al., 2011).
However, another study failed to confirm this finding (Lancaster
et al., 2012). Thus, further studies are needed to conclude whether
the targeting of Tpl2 could improve the complications of obesity.
CONCLUSION
The discovery that metabolic diseases are associated with a low-
grade inflammatory state has opened a new area of research to
understand how inflammation develops and how it impact on
metabolic pathways. It appears that a cross-talk between immune
cells and metabolic cells plays a central role in the disturbance
of metabolic homeostasis. High levels of dietary saturated fatty
acids or of their metabolites can be detected by immune sen-
sors such as TLR or inflammasome leading to the synthesis of
inflammatory cytokines in different metabolic tissues. Dietary fat
can also modify the intestinal microbiota that produces differ-
ent inflammatory molecules leading to an inappropriate immune
reaction. The inflammatory cytokines, saturated fatty acids, and
LPS activate a network of signaling pathways that impinges on
insulin signaling leading to alterations in metabolic cell func-
tions. Hence, the importance of immune sensors and of differ-
ent kinases suggests that new strategies targeting these proteins
could be conceived to improve the metabolic complications of
obesity.
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